DBV Technologies is a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy—delivering antigens through the skin via its Viaskin platform. Its lead programs target food allergies, notably peanut allergy, with the goal of desensitization without oral exposure. The company serves a high-unmet-need niche of patients and caregivers seeking alternatives to traditional allergy management.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -41.9 | — |
| Q3 2025 | 0 | — | -33.2 | — |
| Q4 2025 | 0 | — | -44.8 | — |
| Q1 2026 | 0 | — | -47.6 | — |
| Q2 2026 | 0 | — | -50.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Sagimet Biosciences Inc. (SGMT), Unity Bancorp, Inc. (UNTY), Kearny Financial Corp. (KRNY), Southern First Bancshares, Inc. (SFST), CorMedix Inc. (CRMD), Climb Bio Inc (CLYM)